GeneTether Therapeutics, Inc. (TSE:GTTX) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
GeneTether Therapeutics Inc. has announced a binding term sheet for a private placement aiming to raise between C$250,000 and C$500,000, and an exclusive license agreement for a promising soft tissue sarcoma drug, STS-201, which also shows potential in other cancers. In conjunction with this agreement, the company will appoint John Rothman, Ph.D., with over 30 years of experience, as its consulting Chief Scientific Officer to advance its strategic medical mission.
For further insights into TSE:GTTX stock, check out TipRanks’ Stock Analysis page.
